The last TAAr is the ubiquitin-conjugating enzyme E2C (UBE2C, gene: UBE2C), which emerges as a pivotal oncogene in ovarian cancer, significantly influencing tumor malignancy and resistance to cisplatin chemotherapy by interacting with Cyclin-Dependent Kinase 1 (CDK1). Here, UBE2C is linked to ovarian carcinoma.